1. Introduction {#sec1}
===============

Vascular dementia (VaD) is one of the most common forms of dementia after Alzheimer\'s disease (AD) \[[@B1]\], and the most frequent cause of dementia in the elderly \[[@B2]\]. First described as arteriosclerotic dementia \[[@B3]\], VaD is defined as loss of cognitive function resulting from ischemic, hemorrhagic brain lesions (such as border zone infarcts and ischemic periventricular leukoencephalopathy) or hypoperfusion, due to cerebrovascular disease or cardiovascular pathology \[[@B4]\]. Incomplete microangiopathic infarcts due to fibrohyalinosis are regarded as the major pathophysiological manifestation \[[@B5]\] of VaD. While AD is characterized by memory impairment, VaD is characterized by executive dysfunction \[[@B6]\] and behavioral psychological symptoms such as apathy, abulia, opposition, agnosia \[[@B7]\], anxiety \[[@B8]\], depression \[[@B9]\], and suicidal thoughts \[[@B9]\]. Cognitive impairment is relatively mild as compared to AD.

VaD accounts for approximately 30% of dementia in the world today \[[@B10]\]. In Europe, out of 3.7 million of people with clinical dementia, 800,000 have a diagnosis of VaD \[[@B11]\]. The prevalence rate of VaD is around 1--4% in Western developed nations \[[@B12]\]. Recently, in mainland China, a nationwide investigation found the prevalence of VaD to be around 0.8% \[[@B13]\]. The total annual cost (direct, illness related and cost arise from informal care) of dementia in developing countries is estimated to be at least USD 73 billion \[[@B10]\]. A study in Denmark revealed the annual cost per demented person to be DKK 77,000 (approximately USD 14,114) \[[@B14]\]. Thus, the total healthcare cost for VaD patients is highest among all other forms of dementia \[[@B15]\], and the frequency of VaD is increasing exponentially for people over the age of 65 years old \[[@B16]\]. If current trends continue, VaD will become an increasingly significant public health problem in the 21st century.

Drugs currently used in the treatment of VaD include cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) \[[@B17]\] and non-cholinergics (memantine, nimodipine, hydergine, nicergoline, CDP-choline, folic acid \[[@B18]\], posatirelin, propentofylline, and pentoxifylline \[[@B19]\]). These orthodox medications (OM) have some efficacy \[[@B20]\]. Preventive therapeutic strategies aiming at reducing cerebrovascular risk factors \[[@B17]\] are also considered by patients likely to develop VaD. As yet, there is no compelling evidence that any of these strategies are effective, and no single intervention can be recommended for the prevention of VaD \[[@B21]\]. This creates a difficult and frustrating situation for sufferers of the disease, their caregivers, and healthcare providers \[[@B18]\], as well as for healthy people hoping to avoid developing VaD.

Owing to the limitations of OM and therapeutic prevention, some patients resort to herbal medications (HM). Traditionally, a number of herbs have been used for cognitive disorders. For example, *Artemisia absinthium* (Wormwood) was used in traditional European medicine to restore cognitive functions \[[@B22]\]. *Melissa officinalis* (Lemon balm), also widely used in Europe, has been claimed to restore memory \[[@B23]\]. Since the 16th century, Europe, *Salvia lavandulaefolia* (Spanish sage) and *Salvia officinalis* (common sage) have been reported as being effective for improving memory \[[@B22]\]. *Bacopa monniera* (water hyssop) has been used in Ayurvedic medicine to improve memory and intellectual functions. *Centella asiatica* (Asiatic pennywort), another Ayurvedic remedy, when combined with milk, is also given to improve memory \[[@B24]\]. *Withania somnifera* root is classed among the rejuvenative tonics in Ayurvedic medicine and is known to sharpen memory \[[@B25]\]. *Codonopsis pilosula* root (Dangshen in Chinese), *Biota orientalis* leaves (Cebaiye in Chinese), and *Polygala tenuifolia* root (Yuanzhi in Chinese) have been used in traditional Chinese medicine (TCM) for amnesia \[[@B26], [@B27]\]. Some compounds with cognition-improving properties have been isolated from various plants. EGb 761, an extract from the leaves of the tree *Ginkgo biloba*, originally used in Western medicine for circulatory disorders \[[@B28]\], shows reversal of decline in cognitive function and of cerebral insufficiency in numerous studies \[[@B29]\], and is now mainly used in VaD as well \[[@B30]\]. In another study, hyperforin, isolated from *Hypericum perforatum*, a herb used in Portuguese folk medicine, appears to enhance cognitive function \[[@B31]\].

In China, a nation with its own system of medicine that has been continuously documented over two thousand years, the incorporation of Chinese herbal medicine (CHM) with Western medicine in the treatment of dementia has become a standard in recent decades. *Salvia miltiorrhiza* Bge. (Danshen in Chinese) and *Pueraria thomsonii* Benth. (Gegen in Chinese), commonly used herbs in the Chinese materia medica for the treatment of cardiocerebrovascular symptoms, are well tolerated and effective in improving vascular function and structure. Thus, either one might be able to effectively intervene in the pathophysiological cascade of VaD \[[@B32]\]. An animal study revealed that glossy privet fruit (*Ligustrum lucidum* Ait.), a kidney-tonifying Chinese herbal medicine, inhibits neural cell apoptosis following the onset of vascular dementia by reducing apoptotic signals induced by cerebral ischemia/hypoxia \[[@B33]\]. A number of proprietary herbal medicines may also be effective for VaD. According to a study, Chunghyul-dan, which possesses therapeutic effects for microangiopathy, could be useful to inhibit the development of VaD \[[@B34]\]. Huperzine A (HupA), a cholinesterase inhibitor naturally derived from the Chinese herb *Lycopodium serratum* or *Huperzia serrata*, has even better penetration through the blood-brain barrier, higher oral bioavailability, and longer duration of AChE inhibitory action than tacrine, donepezil, and rivastigmine \[[@B35]\]. Its anticholinesterase activity is stronger than galantamine (a commonly used drug to treat Alzheimer\'s disease and various memory impairments) \[[@B26]\]. Its ability to improve memory deficits in elderly people with VaD and AD has been demonstrated, with minimal peripheral cholinergic side effects and no unexpected toxicity \[[@B35]\]. These reports suggest that comprehensive investigation of the efficacy and safety of HM is worthwhile; the results could lead to better treatment of VaD as well as effective prevention.

In a previously conducted systematic review \[[@B36]\], we looked for clinical trials for Alzheimer\'s disease (AD), and found an even larger number of clinical trials conducted on VaD patients, mainly from mainland China. Because a large proportion of patients have both VaD and AD pathologies \[[@B37]\], and because the current OM treatments for both types of dementia are similar, we have systematically reviewed the clinical trials of HM conducted on VaD patients in this study.

2. Objective {#sec2}
============

This systematic review was conducted to assess the safety and efficacy of HM, as either monotherapy or adjunct to OM in the treatment of VaD.

3. Method {#sec3}
=========

3.1. Inclusion Criteria {#sec3.1}
-----------------------

All published studies reporting randomized, controlled clinical trials comparing HM as monotherapy or adjuvant therapy, with placebo or OM as controls, were included. No restriction on the language of publication was imposed. As there is a lack of a single, specific criterion for the diagnosis of VaD \[[@B38]\], we accepted the use of the following instruments: Diagnostic and Statistical Manual of Mental Disorders (DSM-III, DSM-III-R \[[@B39]\], and DSM-IV \[[@B40]\]), the International Classification of Diseases, 10th Revision (ICD-10) \[[@B41]\]; the State of California Alzheimer\'s Disease Diagnostic and Treatment Centers (ADDTC) scale \[[@B42]\]; the Hachinski Ischemic Scale (HIS) \[[@B43]\]; the National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l\'Enseignement en Neurosciences scale (NINDS-AIREN) \[[@B44]\]. Trials with participants possessing other forms of dementia (Alzheimer\'s disease, Lewy body dementia, and frontotemporal dementia) were excluded. There was no restrictions on the ethnicity, gender, age, or disease duration of the participants in the trials. The HM interventions could be either (1) a single herb, (2) a preparation containing multiple herbs, (3) extracts from an herb, or (4) proprietary herbal products. They had to have been used alone or coadministered with conventional medications (OM). The control intervention had to have been either (1) a placebo, or (2) OM. Trials of all durations were included. Crossover studies were also accepted if the first phase fulfilled the above criteria. Outcome measures of interest were (1) Mini-Mental Status Examination (MMSE) \[[@B45]\], (2) Activities of Daily Living Scale (ADL) \[[@B46]\], and (3) Hasegawa Dementia Scale (HDS) \[[@B47]\]. The safety profile might be represented in (5) adverse effect count, (6) biochemical indications, or (7) number of withdrawals due to adverse events.

3.2. Search Strategy and Method of Review {#sec3.2}
-----------------------------------------

We identified trials from the following electronic databases: (1) Ovid MEDLINE In-Process and Other Non-Indexed Citations and Ovid MEDLINE; (2) CINAHL; (3) EMBASE; (4) EBM Reviews; (5) AMED; (6) ACP Journal Club; (7) Cochrane Central Register of Controlled Trials; (8) Cochrane Database of Systematic Reviews; (9) Cochrane Methodology Register; (10) Database of Abstracts of Reviews of Effects; (11) Health Technology Assessment; (12) National Health Service Economic Evaluation; (13) China National Knowledge Infrastructure (CNKI); (14) Chinese Sci and Tech Journals (VIP); (15) CBM disc; (16) China Doctor Dissertations Full-Text Database; (17) China Master Theses Full-text Database. The search conducted in March 2011 followed a strategy ([Table 1](#tab1){ref-type="table"}) developed with reference to a Cochrane review on herbal medicine \[[@B48]\], regardless of language and publication status. Hand-search of a list of Chinese and English journals was carried out to find the latest studies. We also referred to the reference lists of relevant papers to identify potential studies.

Two independent reviewers (K. W. Chan and S. C. Man) assessed the trials for their eligibility. The inclusion of trials was confirmed upon consensus of reviewers. Risk of bias assessment of the trials was performed according to the revised Consolidated Standards of Reporting Trials (CONSORT) statement \[[@B49]\]. Any disagreement was settled by discussion.

4. Results {#sec4}
==========

4.1. Description of Included Studies {#sec4.1}
------------------------------------

Using the search strategy as described, 116 studies were identified. Upon full-text examination we excluded 69, on the basis that (1) 13 were not randomized controlled trials, (2) four were repeat publications, (3) three did not state their inclusion criteria, (4) one included other forms of dementia, (5) 44 did not disclose adequate baseline information, and (6) four involved the use of non-HM intervention, such as acupuncture. These disqualifications left 47 studies for this systematic review.

There were a total of 3725 participants (2423 male, 1302 female) in the 47 included trials. Among them, three had cross-over design while the remaining were parallel design studies. The age of participants ranged from 45--89 years old, and their disease duration ranged from two months to 12 years. Thirty-two studies were performed in a single center; one was performed in multiple centers; 14 trials did not give this information. The duration of trials lasted from one to seven months. All of the trials were conducted in mainland China, and all the subjects were of Chinese ethnicity.

4.2. Risk of Bias ([Table 2](#tab2){ref-type="table"}) {#sec4.2}
------------------------------------------------------

We adopted the checklist of items suggested by CONSORT \[[@B50]\] in the evaluation of methodological quality (risk of bias). The checklist was divided into five sections, namely, title and abstract, introduction, methods, results, and discussion.

Except for 4 studies \[[@B51]--[@B54]\], all had adequate information on the title and abstract. Four studies \[[@B55]--[@B58]\] did not give an appropriate introduction.

With regard to method, none of the 47 studies reported details for sample size calculations. Eight \[[@B51]--[@B54], [@B57], [@B59]--[@B61]\] did not clearly state their objective of study. All but one study \[[@B62]\] poorly reported their randomization and blinding. Statistical method was not reported in 13 studies \[[@B51]--[@B53], [@B58], [@B59], [@B63]--[@B70]\].

For the results section, only two studies \[[@B62], [@B71]\] reported with a flowchart. Patient recruitment, outcomes and estimation, and ancillary analyses were mentioned by the majority of studies. More than half of the studies did not report adverse event count.

In the discussion section, both the interpretation and overall evidence were adequately reported by the studies; generalizability, however, was not sufficiently illustrated by 13 studies.

4.3. Randomization ([Table 2](#tab2){ref-type="table"}) {#sec4.3}
-------------------------------------------------------

All of the included studies claimed to have allocated participants randomly to study groups. Six \[[@B72]--[@B77]\] reported the use of computer-generated sequences; the other 41 studies did not provide any description of how randomization was achieved.

4.4. Allocation Concealment ([Table 2](#tab2){ref-type="table"}) {#sec4.4}
----------------------------------------------------------------

Except for one study \[[@B71]\] which clearly stated that it did not use any blinding methods, 32 studies did not report whether they applied blinding or not. For those studies which reported the use of allocation concealment, 6 were single blind \[[@B52], [@B57], [@B66], [@B78]--[@B81]\], and 8 were double blind \[[@B55], [@B56], [@B62], [@B76], [@B82]--[@B85]\].

4.5. Eligible Criteria ([Table 3](#tab3){ref-type="table"}) {#sec4.5}
-----------------------------------------------------------

Only two studies \[[@B82], [@B86]\] used a single diagnostic criterion to select participants. Other studies used two or more diagnostic criteria. Among them DSM III and IV were the most commonly adopted (42 studies used it) \[[@B39], [@B40]\]. The other criteria commonly used, listed in descending order of frequency, were HIS \[[@B43]\] (27 studies), MMSE \[[@B45]\] (25 studies); HDS \[[@B47]\] (17 studies); ADL \[[@B46]\] (11 studies); clinical dementia rating scale (CDR) \[[@B87]\] (6 studies); NINDS-AIREN \[[@B44]\] (five studies); ICD-10 \[[@B41]\] (four studies). Other measurement scales used included the scale for the differentiation of syndromes of vascular dementia (SDSVD) \[[@B88]\], Functional Activities Questionnaire (FAQ) \[[@B89]\], and self-derived criteria (SELF). Furthermore, some studies also carried out diagnostic imaging such as CT and magnetic resonance imaging (MRI) for participant selection.

4.6. Baseline Characteristics and Outcome Measures ([Table 3](#tab3){ref-type="table"}) {#sec4.6}
---------------------------------------------------------------------------------------

A number of batteries were employed to evaluate the baseline characteristics and outcome measures. The most commonly employed set of evaluative questionnaires included MMSE \[[@B45]\] (38 studies); HDS \[[@B47]\] (23 studies); ADL \[[@B46]\] (20 studies); Berg Balance Scale (BBS 8 studies); SELF (5 studies); memory quotient (MQ 1 study); geriatric dementia scale (GDS 1 study). Moreover, diagnostic imaging such as electroencephalography (EEG 6 studies) and CT (2 studies) were carried out. A number of studies also took into account the changes in hemodynamics (21 studies) and transcranial doppler (TCD 3 studies) as part of the outcome measures. Lastly, biochemical analysis, such as changes in the level of superoxidase dismutase (SOD), malondialdehyde (MDA), homocysteine (HCY), testerone (T), and 17 beta-estradiol (E2) were also adopted in assessing the efficacy and safety of interventions in the studies.

The different batteries used in the studies resulted in variation in outcome measures. As the data were not suitable for meta-analysis, only qualitative appraisal could be carried out.

4.7. Herbal Medicine as Monotherapy ([Table 3](#tab3){ref-type="table"}) {#sec4.7}
------------------------------------------------------------------------

There were altogether 43 trials testing herbal medicine as a monotherapy for VaD. Among them 15 studies compared different HM preparations with Piracetam alone (a nootropic agent). One study compared HM with another stronger nootropic compound Aniracetam. One study compared HM with Piracetam + hydergine and one study compare HM with Piracetam + Vitamin E + respiratory stimulant Duxil (Almitrine). Hydergine, (also known as ergoloid mesylates, another nootropic agent), was tested alone against HM in 11 studies. Five studies reported HM having similar efficacy to these nootropics; the remaining 23 claimed HM to be significantly better.

Seven studies compared HM with Duxil (Almitrine) alone, a respiratory stimulant originally used to treat patients with chronic obstructive pulmonary disease. In one study, HM is compared with Duxil + Nimodipine (a dihydropyridine calcium channel blocker for the treatment of high blood pressure). One study reported HM to have similar efficacy with Duxil; the other seven claimed that HM is better than Duxil.

Furthermore, HM was compared with Nimodipine in two studies, Huperzine A in one study, cerebroprotein hydrolysate in one study, and placebo in three studies. All of these studies concluded that HM is better than the control intervention.

4.8. Herbal Medicine as an Adjunct Therapy ([Table 3](#tab3){ref-type="table"}) {#sec4.8}
-------------------------------------------------------------------------------

Four trials evaluated HM as an adjunct therapy for VaD. Two of them evaluated the adjunct effect of the CHM decoction BuYangHuanWuTang. Wang compared it with the coadministration of Piracetam and Nimodipine; Yan compared it with the co-administration of Aniracetam, Nimodipine, together with the injection of cerebroprotein hydrolysate. Shi and Wang studied the CHM decoction which, according to TCM theory, could "tonify the kidney, activating blood," and tested its adjunct effect with nimodipine + hydergine (In TCM theory, the brain is considered an outgrowth of "kidney" energy. Neurodegenerative disorders such as dementia are caused by stagnation of "blood," accumulation of "phlegm," and deficiency of the "kidney." In order to resist or halt the condition, TCM treatment targets the nourishment of the kidney by means of "kidney invigorating," "blood activating" and "phlegm dissipating" herbal decoctions \[[@B90]\]. Guo et al. \[[@B53]\] studied another CHM BuNaoTongQiao decoction, which possesses nootropic properties, according to TCM theory, and compared it with Duxil. All these studies reported that when HM is used together with Western medications, both the efficacy and safety of OM could be enhanced.

4.9. Adverse Events and Withdrawal ([Table 3](#tab3){ref-type="table"}) {#sec4.9}
-----------------------------------------------------------------------

Among those 43 studies which tested HM as monotherapy, 25 studies did not report any cases of withdrawal. Ten studies claimed they did not observe any adverse events in groups treated with HM. Eight studies reported a number of mild adverse events, such as mouth dryness, sore throat, constipation, nausea, loss of appetite, and dyspepsia. These adverse events could be resolved without treatment. Serious adverse events were not observed. Occurrence of adverse events remained unclear in the four studies which tested HM as adjunct therapy.

The dropouts or withdrawals were unclear in 44 out of 47 studies. Wu et al. \[[@B83]\] reported two dropouts in the course of intervention. Liu et al. \[[@B71]\] reported 46 dropouts during his trial. Cui et al. \[[@B77]\] reported five dropouts.

5. Discussion {#sec5}
=============

5.1. A Wide Variety of Herbal Remedies {#sec5.1}
--------------------------------------

Thirty-one out of 47 studies tested herbal mixtures prepared in the form of granules or capsules. Fifteen studies tested their herbal mixtures in the form of decoctions. One study tested the extract from a single herb. As some of the studies tested the same herbal mixture, altogether 42 different herbal mixtures were tested among these 47 studies ([Table 4](#tab4){ref-type="table"}). These herbal mixtures or extracts, according to the TCM theory, have the ability to "tonify the "kidney," activate blood." Despite the absence of pharmacological studies to verify their safety, these studies reported encouraging effects and high safety profiles. Upon further analysis of the constitutional ingredients in these herbal formulas, we ranked the 30 most commonly used herbal constituents together according to the dosages ([Table 5](#tab5){ref-type="table"}).

The first five in descending order of frequency of use are Rhizoma Chuanxiong (Chuanxiong in Chinese), Radix Polygoni Multiflori (Heshouwu in Chinese), Radix Astragali (Huangqi in Chinese), Radix Ginseng (Renshen in Chinese), and Rhizoma Acori Tatarinowii (Shichangpu in Chinese).

Rhizoma Chuanxiong, originates from the plant *Ligusticum chuanxiong* Hort., which is used in TCM to "remove blood stasis." Chemical analysis shows that it possesses an alkaloid named ligustrazine, which has antioxidant, anti-inflammatory, antifibrosis, and immune-modulative properties \[[@B91]\]. A clinical study is being carried out to evaluate its effect on patients\' recovery from cerebral vascular accidents \[[@B92]\]. The root of *Polygonum multiflorum* Thunb. (Radix Polygoni Multiflori in English, the Chinese name is Heshouwu), commonly known as fleece flower root, is another popular HM used to treat premature aging and dementia. Past studies have shown it to have activity that may contribute to cardiovascular protection \[[@B93]\]. Long-term pretreatment with it may protect the brain against focal cerebral ischemia \[[@B94]\]. One animal study also suggests that it has anti-oxidant properties \[[@B95]\], with the capacity to prevent cognitive deficits \[[@B96]\], possibly even to promote learning and enhance memory \[[@B97]\]. A medical team in Taiwan is proposing a phase II clinical trial to assess the efficacy and safety of a new drug derived from it \[[@B98]\]. Radix Astragali (Huangqi), from *Astragalus membranaceus* (Fisch.) Bge. var. *mongholicus* (Bge.) Hsiao, a commonly used herb to "vitalize spleen Qi" and "treat circulatory disorders" in TCM, possesses various components (astragalus saponins, astragalus polysaccharide) demonstrated to have anti-oxidation properties. These, together with its anti-cholinergic property, have been suggested to be the source of its significant anti-dementia effect \[[@B99]\]. A clinical trial is being carried out to determine the effect of an HM capsule with Radix Astragali (Huangqi in Chinese) as the main constituent on ischemic stroke \[[@B92]\]. Radix Salviae Miltiorrhizae (Danshen in Chinese), the root of *Salvia miltiorrhiza* Bge., is used to "activate blood and resolve stasis" according to TCM. A laboratory study of its triterpenoids-enriched extract revealed that its antiatherogenic property was mediated by an anti-inflammatory mechanism \[[@B100]\]. Another animal study of Radix Salviae Miltiorrhizae (Danshen) reports it to reduce the area of cerebral infarct in ischemia-reperfusion injured rats, suggesting it has potential in the treatment of cerebral infarct in humans \[[@B101]\]. Radix Ginseng (Rensheng), the root of *Panax ginseng* C.A. Mey., is a popular notifying herb in TCM, and its ginsenosides have been found to have protective effects on memory via antiapoptosis in a rat model with vascular dementia \[[@B102]\], and to stimulate angiogenesis and tissue regeneration \[[@B103]\], suggesting that it has potential to help VaD patients. In a Korean clinical study, Radix Ginseng was reported to be clinically effective in improving the cognitive performance of AD patients \[[@B104]\]. Rhizoma Acori Tatarinowii (Shichangpu), also named grassleaf or sweet-flag rhizome, the rhizome of *Acorus tatarinowii* Schott., is used in TCM for resuscitation after coma. Pharmacological studies suggest this effect may be due to the increase in permeability of the blood-brain barrier \[[@B105]\]. In another pharmacological study, the fruit of *Cornus officinalis* Sieb. et Zucc. (Shanzhuyu in Chinese), which is used in TCM to "tonify the kidney," was found to possess an extract that has protective effects against oxidative stress-induced neurotoxic processes \[[@B106]\]. Other experimental reports have indicated that the triterpenoid saponins from the roots of *Polygala tenuifolia* Willd. (Yuanzhi) possess neuroprotective effects \[[@B107], [@B108]\]. Study on extracts of *Alpiniae Oxyphyllae* Miq. (Fructus Alpinae Oxyphyllae in English, the Chinese name is Yizhi) have found evidence that it protects neurons against ischemia-induced cell death \[[@B109]\] and that it prevents glutamate-induced apoptosis in cortical neurons \[[@B110]\]. In another study, it was reported that *Rhizoma Polygonati* (known as Huangjing in Chinese, used in TCM as a notifying agent) could improve learning and memory in a scopolamine-induced mouse model of dementia by reducing the damaging effects of cerebral ischemia and anti-oxidation, having similar effects to those provided by vitamin E \[[@B111]\]. In a study to examine the anti-oxidative and neuroprotective effects of *Paeonia lactiflora* Pall. (Baishao in Chinese), it was found to suppress the hydrogen peroxide-induced apoptosis in PC12 cells, suggesting that it could be a new antioxidant useful in the prevention of neuronal diseases \[[@B112]\]. Rhizoma Gastrodiae from *Gastrodia elata* Bl. (Tianma in Chinese), a classic HM used to "extinguish wind and arrest convulsions" in TCM theory, possesses vasodilating \[[@B113]\], anti-inflammatory, and antiangiogenic activities \[[@B114]\], suggesting a potential VaD treatment. The total alkaloids found in Radix Codonopsis (Dangshen in Chinese used in TCM to "tonify Qi") have been reported to potentiate neurite outgrowth induced by nerve growth factor in PC12 cells \[[@B115]\]. Glossy privet fruit, from *Ligustrum lucidum* Ait. (Nüzhenzi in Chinese), a kidney-tonifying HM, can inhibit cell apoptosis by reducing apoptotic signals induced by cerebral ischemia/hypoxia \[[@B33]\].

5.2. Study Weaknesses {#sec5.2}
---------------------

Though all the studies reported promising results of HM in the treatment of VaD, they demonstrated a number of weaknesses as well. The evidence drawn from the studies was insufficient for us to confirm the safety and efficacy of HM, because of the following issues

1.  The sample sizes of the studies ranged from 18 to 300, and none of them reported sample size calculations, as suggested by the CONSORT statement. Treatment effects can be exaggerated when sample size is inappropriate, and thus the results of these studies may not be conclusive.

2.  Different diagnostic criteria were used in the studies. Some of these criteria were even self-derived and their validities remained unknown. This produced much discrepancy.

3.  Differences in the baseline characteristics of the subjects limit the extent to which results can be compared with each other.

4.  Though all of the studies claimed to have participants allocated randomly, only a few reported the method of randomization. For those studies without detailed descriptions of randomization, we could not rule out the possibility of bias. Furthermore, unclear descriptions of allocation concealment, dropouts, and intention-to-treat analysis further hamper the ability to assess the validity of the evidence reported by these studies.

5.  Outcome measures varied and were incomplete in the studies. Some investigators employed self-developed scales, which could not be, or had not been, independently evaluated for their sensitivity and specificity. The validity is further questionable due to insufficient or inappropriate statistical treatment. Though meta-analysis techniques such as vote-counting may have been used for the analysis of the data, we avoid to do so because (1) the statistical significance or size of the results of the individual studies are ignored; and (2) vote-counting takes no account of the differential weights given to each study. \[[@B116]\]

6.  Different HM were tested in the 47 studies included here, with great variation in terms of composition, dosage, and duration of interventions. This renders comparison of the studies impossible, and thus quantitative analysis could not be carried out.

7.  A number of studies (30 out of 47) did not mention safety issues. The investigators of these studies may have underestimated possible adverse events, and the safety of HM in these studies could not be guaranteed.

5.3. Implications for Further Studies {#sec5.3}
-------------------------------------

Regarding the published studies, methodology quality is the leading should concern. It is recommended that future clinical studies follow the guidelines as suggested by CONSORT to minimize bias as well as to ensure high validity, statistically reliable results and to permit comparison with other studies. Researchers should explicitly report methods for calculation of sample size. Widely recognized diagnostic criteria and outcome measures should be used. It is highly recommended to incorporate medical imaging techniques (such as perfusion computed tomography) to confirm the diagnosis of VaD. Appropriate statistical analyses should be carried out for baseline data and outcome results; long-term followup is also recommended and highly desirable.

Our review has identified the individual herbs that appear most frequently in formulas for VaD. The top five are Rhizoma Chuanxiong (Chuanxiong), Radix Polygoni Multiflori (Heshouwu), Radix Astragali (Huangqi), Radix Ginseng (Renshen), and Rhizoma Acori Talarinowii (Shichangpu). The clinical efficacy and safety of these herbs, over centuries of use and during recent controlled studies, are a powerful combination of attributes. We believe that further high-quality clinical studies on these individual constituents, as well as the herbal mixtures resulted, could lead to the discovery of new drugs for effective treatment and prevention of VaD.

6. Conclusion {#sec6}
=============

Currently available RCTs suggested that HM might be more effective and safer than OM for treatment of VaD. However, these studies have a number of weaknesses, mainly due to their methodological insufficiencies. With regard to the reports that did meet our selection criteria, the results indicated that HM, in a predominance of instances, can be superior to OM and useful in the treatment of VaD. Further multicenter trials with large sample sizes, high methodological quality, and standardized HM ingredients are needed to confirm the value of HM in treating VaD, in order to establish specific clinical recommendations.
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###### 

Search strategy.

  ---- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1    exp Plant Extracts/or exp Drugs, Chinese Herbal/or exp Plants, Medicinal/or exp Medicine, Chinese Traditional/or exp China/or chinese medicine.mp. or exp Medicine, Oriental Traditional/or exp Phytotherapy/
  2    drugs non prescription.mp. or exp Drugs, Non-Prescription/
  3    medicinal herbs.mp
  4    herbs medicinal.mp.
  5    drugs non prescription.mp. or exp Drugs, Non-Prescription/
  6    alternative medicine.mp. or exp Complementary Therapies/
  7    complementary medicine.mp.
  8    Phytotherapy/or Plants, Medicinal/or Plant Extracts/or Herb-Drug Interactions/or herbs.mp. or Drugs, Chinese Herbal/or Plant Preparations/
  9    exp Phytotherapy/or exp Plants, Medicinal/or exp Plant Extracts/or exp Herb-Drug Interactions/or exp Alkaloids/or herbs.mp. or exp Drugs, Chinese Herbal/or exp Plant Preparations/
  10   1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
  11   randomized controlled trials.mp. or exp Randomized Controlled Trials/
  12   exp Random Allocation/or exp Clinical Trials/or exp Double-Blind Method/or double blind.mp. or exp Placebos/
  13   single blind.mp. or exp Single-Blind Method/
  14   clinical trials.mp.
  15   prospective studies.mp. or exp Prospective Studies/
  16   follow up studies.mp. or exp Follow-Up Studies/
  17   11 or 12 or 13 or 14 or 15 or 16
  18   exp Mental Retardation/or exp Dementia/or exp vascular dementia/or progressive brain disorder.mp. or exp Memory Disorders/
  19   (vascular dementia).mp.
  20   18 or 19
  21   10 and 17 and 20
  ---- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Methodological quality of studies (CONSORT checklist).

                                   Reported page number of each item^∗1^                                                                                                                                        
  ---- -------------------- ------ --------------------------------------- ------ ------ ------ ------ ------ --- ----- ----- ------ ------ ------ ----- ------ ------ ------ ------ ----- ------ ------ ------ ------
  1    Wan et al.           1998   25                                      25     25     25     24     25     U   U     U     U      U      U      U     U      25     26     26     U     U      27     U      27
  2    Zhao et al.          1999   585                                     585    585    586    585    586    U   U     U     U      U      586    U     585    585    585    586    U     587    587    587    587
  3    Ji                   2000   10                                      10     10     11     U      11     U   U     U     U      U      U      U     10     10     U      11     U     U      11     U      11
  4    Lu et al.            2000   290                                     290    290    290    290    290    U   U     U     U      U      290    U     U      290    290    290    U     U      290    U      290
  5    Luo                  2001   470                                     U      470    470    470    471    U   U     U     U      470    471    U     470    470    472    472    472   U      472    473    473
  6    Zhang et al.         2001   U                                       51     51     51     U      51     U   U     U     U      U      U      U     51     51     52     52     U     52     52     52     52
  7    Zhou and Yi          2001   14                                      14     14     14     14     14     U   U     U     U      U      U      U     U      14     15     15     U     U      15     U      15
  8    Cao et al.           2002   80                                      80     80     80     80     80     U   U     U     U      80     81     U     80     80     81     81     U     81     81     U      81
  9    Hong et al.          2002   U                                       3      3      3      U      3      U   U     U     U      U      3      U     3      3      4      4      4     U      5      5      5
  10   Huang et al.         2002   301                                     301    301    302    301    302    U   U     U     U      U      302    U     U      302    301    302    U     U      303    303    303
  11   Liu et al.           2002   526                                     526    526    526    526    526    U   U     U     U      U      U      U     526    526    U      527    U     U      527    U      527
  12   Wang et al.          2002   U                                       295    296    296    U      296    U   U     U     U      U      U      U     295    295    296    296    U     U      296    U      296
  13   Yang et al.          2002   48                                      48     49     49     48     49     U   U     U     U      48     49     U     U      48     49     49     U     U      50     51     51
  14   Cai et al.           2003   482                                     482    482    482    482    482    U   482   U     U      U      483    U     U      482    483    483    U     483    483    483    483
  15   Guo et al.           2003   U                                       931    931    931    U      931    U   U     U     U      U      U      U     U      931    931    931    U     U      931    U      931
  16   Jia et al.           2003   20                                      20     20     20     20     21     U   U     U     U      U      21     U     20     20     21     21     U     21     22     U      22
  17   Cheng et al.         2004   16                                      16     16     16     16     16     U   U     U     U      U      16     U     U      16     17     17     U     U      17     17     17
  18   Liao et al.          2004   112                                     112    112    113    112    113    U   U     U     U      U      113    U     113    112    113    113    U     113    113    114    114
  19   Shen and Du          2004   41                                      41     42     42     41     42     U   U     U     U      U      42     U     42     42     42     43     U     U      43     43     43
  20   Wang et al.          2004   679                                     679    679    680    679    680    U   680   680   680    680    680    681   U      679    680    680    U     681    681    681    681
  21   Wang et al.          2004   1691                                    1691   1691   1692   1691   1692   U   U     U     U      U      1692   U     1691   1691   1692   1692   U     U      1693   U      1693
  22   Wu et al.            2004   3                                       3      3      3      3      3      U   U     U     U      3      3      U     U      3      4      4      U     4      4      U      4
  23   Yu et al.            2004   424                                     424    424    424    424    424    U   U     U     U      424    U      U     424    424    425    425    U     425    425    425    425
  24   Zhao                 2004   8                                       9      9      9      8      9      U   U     U     U      U      9      U     9      9      9      9      U     9      9      U      10
  25   Feng et al.          2005   520                                     520    520    520    520    520    U   U     U     U      U      521    U     520    520    521    521    U     U      521    522    521
  26   Liu                  2005   50                                      50     50     50     50     50     U   U     U     U      U      50     51    50     51     51     51     U     51     51     51     51
  27   Liu et al.           2005   1052                                    1052   1052   1052   U      1052   U   U     U     U      U      1053   U     1053   1052   1053   1053   U     1054   1054   1054   1054
  28   Liu and Chen         2005   18                                      18     18     19     18     19     U   U     U     U      U      19     U     U      18     19     19     U     U      20     U      20
  29   Tang et al.          2005   426                                     426    426    427    426    427    U   U     U     U      U      427    U     426    426    427    427    U     427    427    427    427
  30   Wang et al.          2005   93                                      U      93     94     93     94     U   94    94    U      94     94     U     93     94     94     94     U     95     94     U      94
  31   Wang, Chen and Bai   2005   3                                       3      3      3      3      4      U   U     U     U      U      4      U     3      3      3      4      U     U      4      5      5
  32   Wang et al.          2005   260                                     260    261    261    260    261    U   U     U     U      261    261    U     U      260    261    261    U     261    262    U      262
  33   Wang                 2005   40                                      40     40     40     40     40     U   U     U     U      U      40     U     40     40     40     41     U     U      41     41     41
  34   Zhou et al.          2005   11                                      11     11     11     11     12     U   U     U     U      U      12     U     11     11     12     12     U     U      13     U      13
  35   Gao                  2006   14                                      14     14     14     14     15     U   U     U     U      U      U      U     14     14     15     15     U     U      16     U      16
  36   Hao et al.           2006   424                                     424    424    424    424    424    U   U     U     U      U      425    U     U      424    425    425    U     425    425    U      425
  37   Li et al.            2006   48                                      48     48     48     U      48     U   U     U     U      U      48     U     48     48     48     48     U     U      49     49     49
  38   Mou                  2006   1607                                    1607   1607   1607   1607   1607   U   U     U     U      U      U      U     U      1607   1607   1607   U     1607   U      U      1607
  39   Shi and Wang         2006   200                                     200    200    200    200    200    U   200   U     U      200    200    U     U      200    201    201    U     U      201    201    201
  40   Zhang and Lu         2006   680                                     680    680    680    680    681    U   U     U     U      U      U      U     U      680    681    681    U     U      681    681    681
  41   Chen et al.          2007   866                                     866    866    867    866    867    U   867   U     U      867    867    U     866    866    867    867    U     U      868    868    868
  42   Cui et al.           2007   64                                      64     64     64     64     64     U   64    U     U      U      65     U     64     64     U      65     U     U      65     U      65
  43   He                   2007   60                                      U      60     60     U      60     U   U     U     U      60     60     U     U      60     60     60     U     61     61     U      61
  44   Jin et al.           2007   1657                                    1657   1657   1658   1657   1658   U   U     U     1658   1658   1658   U     U      1657   1658   1658   U     1659   1659   1659   1659
  45   Yan                  2007   41                                      U      41     41     41     41     U   U     U     U      U      U      U     U      41     41     41     U     U      41     41     42
  46   Chang                2008   241                                     240    240    241    240    241    U   U     U     U      U      U      U     240    241    241    241    U     241    241    U      241
  47   Li et al.            2008   369                                     369    369    370    369    370    U   U     U     U      U      370    U     369    369    370    370    U     371    371    371    371

Key ^∗1^: U = the relevant item was not found in the paper.

###### 

Study properties.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
       Study                                                        Design                                                                                                                          Sample and characteristics                                         Diagnostic criteria                                                                                                                                                             Herbal intervention                                                                                      Control                                                                                    Outcome measures                                                                                                                                               ITT^∗1^   Drop out^∗2^   ADR^∗3^
  ---- ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------- --------- -------------- ----------------------------------------
  1    Wan et al. \[[@B63]\], China Monotherapy Unclear center      Randomized: method not mentioned; double blinding not mentioned; parallel design; 2 months duration                             68 VaD patients, age: 58--82; duration: 4.37--15.85 yr             DSM-3-R, HDS, HIS, "TCM dementia differential criteria"^∗a^                                                                                                                     Fucong 150 mL,\                                                                                          Piracetam\                                                                                 MMSE, HDS, BEAM, hemodynamic changes                                                                                                                           N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       bid (37)                                                                                                 0.8 g, tid (31)                                                                                                                                                                                                                                                                    

  2    Zhao et al. \[[@B74]\], China Monotherapy Single center      Randomized: method not mentioned; single blind; parallel design; 2 months duration                                              46 VaD patients; age: 57--76; duration: 6 m --1 yr                 DSM-4, HIS, HDS, MMSE, "Protocol for new herbal drugs study on dementia"^∗\ b^                                                                                                  Xianlong\                                                                                                Hydergine\                                                                                 TCD, hemodynamic changes                                                                                                                                       N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       2.7 g, bid (24)                                                                                          3 mg, bid (22)                                                                                                                                                                                                                                                                     

  3    Ji \[[@B59]\], China Monotherapy Unclear center              Randomized: method not mentioned; double blinding not mentioned; parallel design; 2 months duration                             68 VaD patients; age: 58--82; duration: 1.45-3.24  yr              DSM-3-R, HDS, HIS, "TCM dementia differential criteria"^∗\ a^                                                                                                                   Dangguishaoy\                                                                                            Piracetam\                                                                                 MMSE, HDS                                                                                                                                                      N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       ao bid (37)                                                                                              0.8 g, tid (31)                                                                                                                                                                                                                                                                    

  4    Lu et al. \[[@B124]\], China Monotherapy Unclear center      Randomized: method not mentioned; double blinding not mentioned; parallel design; 60 days duration                              50 VaD patients; age: 56--82; duration: 2--6 yr                    DSM-3-R, MMSE, "TCM diagnostic criteria, differentiation and outcome measures on senile dementia"^∗\ c^                                                                         Shentong 10 g,\                                                                                          Hydergine\                                                                                 MMSE, BBS                                                                                                                                                      N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       tid (30)                                                                                                 1 mg, tid (20)                                                                                                                                                                                                                                                                     

  5    Luo et al. \[[@B55]\], China Monotherapy Multicenter         Randomized: method not mentioned; double blind: method not mentioned; parallel design; 75 days duration                         68 VaD patients; age: 49--79; duration: 0.99--2.07 yr              DSM-4, ICD 10, HIS, "TCM diagnostic criteria, differentiation and outcome measures on senile dementia"^∗\ c^                                                                    Shenmayizhi\                                                                                             Hydergine\                                                                                 MMSE, ADL, BEAM, Neurological deficits                                                                                                                         N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       1 g, tid (35)                                                                                            1 mg, tid (33)                                                                                                                                                                                                                                                                     

  6    Zhang et al. \[[@B51]\], China Monotherapy Unclear center    Randomized: method not mentioned; double blinding not mentioned; parallel design; 3 months duration                             61 VaD patients; age: 60--77; duration: 6 m--2.5 yr;               NINDS-AIREN, HIS, HDS, "protocol for new herbal drugs study on dementia"^∗\ b^                                                                                                  Jiannaotongluo\                                                                                          Aniracetam\                                                                                HDS, hemodynamic changes                                                                                                                                       N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       1.6 g, tid (30)                                                                                          0.3 g, tid (31)                                                                                                                                                                                                                                                                    

  7    Zhou and Yi \[[@B64]\], China Monotherapy Single center      Randomized: method not mentioned; double blinding not mentioned; parallel design; 3 months duration                             46 VaD patients; age: 60--80; duration: 8 m--3 yr                  DSM-3, "protocol for new herbal drugs study on dementia,"^∗b^ "protocol for new herbal drugs study on stroke"^∗\ b^                                                             Yinaoling\                                                                                               Piracetam\                                                                                 HDS, FAQ, CCSE                                                                                                                                                 N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       40 mL, bid (23)                                                                                          0.8 g tid (23)                                                                                                                                                                                                                                                                     

  8    Cao et al. \[[@B82]\], China Monotherapy Unclear center      Randomized: method not mentioned; double blind: method not mentioned; parallel design; 60 days duration                         53 VaD patients; age: 58--75; duration: 3 m--12 m                  DSM-4                                                                                                                                                                           Congsheng\                                                                                               Hydergine\                                                                                 MMSE, BBS, TCD, EKG, SELF                                                                                                                                      N         N              N
                                                                                                                                                                                                                                                                                                                                                                                                                                                       tid (25)                                                                                                 tid (28)                                                                                                                                                                                                                                                                           

  9    Hong et al. \[[@B54]\], China Monotherapy Single center      Randomized: method not mentioned; double blinding not mentioned; parallel design; 60 days duration                              86 VaD patients; age: 45--76; duration: 5 m--3 yr                  DSM-4, MMSE, "TCM diagnostic criteria, differentiation and outcome measures on senile dementia,"^∗\ c^ CORELATION, HIS                                                          Shouxing\                                                                                                Piracetam\                                                                                 MMSE, ADL                                                                                                                                                      N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       tid (48)                                                                                                 tid (38)                                                                                                                                                                                                                                                                           

  10   Huang et al. \[[@B125]\], China Monotherapy Unclear center   Randomized: method not mentioned; double blinding not mentioned; parallel design; 3 months duration                             58 VaD patients; age: 57--79; duration: 6 m--3 yr                  DSM-4, MMSE, ADL, HIS, "TCM diagnostic criteria, differentiation and outcome measures on senile dementia"^∗\ c^                                                                 Naohuandan\                                                                                              Piracetam\                                                                                 MMSE, ADL, E2, T, hemodynamic changes                                                                                                                          N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       62 g/d (28)                                                                                              tid (28)                                                                                                                                                                                                                                                                           

  11   Liu et al. \[[@B65]\], China Monotherapy Unclear center      Randomized: method not mentioned; double blinding not mentioned; parallel design; 2 months duration                             64 VaD patients; age: 54--81; duration: 0.8--3 yr                  DSM-4, HIS, CT, MRI                                                                                                                                                             Tongqiaohuoxue-\                                                                                         Duxil 1 tablet\                                                                            MMSE, HDS, hemodynamic changes                                                                                                                                 N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       buyanghuanwu\                                                                                            bid (28)                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                       bid (36)                                                                                                                                                                                                                                                                                                                                                                                    

  12   Wang et al. \[[@B52]\] Monotherapy Single center             Randomized: method not mentioned; single blind: method not mentioned; parallel design; 30 days duration                         300 VaD patients; age: 52--83; duration: 7 m--7 yr                 DSM-3-R, DSM-4, MMSE, "TCM diagnostic criteria, differentiation and outcome measures on senile dementia,"^∗\ c^ HIS, CT, MRI                                                    Yizhitongluo\                                                                                            Piracetam\                                                                                 MMSE, HDS, GDS, ADL, hemodynamic changes, SELF                                                                                                                 N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.9--1.2 g TID (200)                                                                                     0.8 g tid (100)                                                                                                                                                                                                                                                                    

  13   Yang et al. \[[@B80]\], China Monotherapy Single center      Randomized: method not mentioned; single blind: method not mentioned; parallel design; 2 months duration                        90 VaD patients; age: 50--81; duration: 3 M--6.5 yr                DSM-4-R, ICD10, CDR, MMSE, HDS-R, CORNELL, "protocol for new herbal drugs study on dementia"^∗\ b^                                                                              Zhinao 1.5 g\                                                                                            Hydergine\                                                                                 MMSE, HDS, ADL, neurological deficits, hemodynamic changes, TCD, EEG, "TCM diagnostic criteria, differentiation and outcome measures on senile dementia"^∗c^   N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       tid (60)                                                                                                 2 mg tid (30)                                                                                                                                                                                                                                                                      

  14   Cai et al. \[[@B72]\], China Monotherapy Center unclear      Randomized: computer generated sequence; single blind: method not mentioned; parallel design; 3 months duration                 63 VaD patients; age: 65--78; duration: 3 m--94 m                  DSM-4-R, MMSE, HIS, CT, MRI                                                                                                                                                     Kangxing\                                                                                                Hydergine\                                                                                 MMSE, ADL, hemodynamic changes, "protocol for new herbal drugs study on stroke" *中藥*  *新*  *藥治療*\                                                        N         Y              N
                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.9 g tid (33)                                                                                           2 mg tid (30)                                                                              *癡呆的*  *臨* \                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           *床研究指導原則*                                                                                                                                                                        

  15   Guo et al. \[[@B53]\], China\                                Randomized: method not mentioned; double blinding not mentioned; parallel design; 2 months duration                             53 VaD patients; age: 55--73; duration: 1 yr--5 yr                 DSM-4, "protocol for new herbal drugs study on dementia,"^∗\ b^ "protocol for new herbal drugs study on stroke"^∗\ b^                                                           Bunaotongqiao\                                                                                           Duxil 1 tablet\                                                                            MMSE, HDS, hemodynamic changes,                                                                                                                                N         N              U
       Adjunct therapy\                                                                                                                                                                                                                                                                                                                                                                                                                                + Duxil 1 tablet\                                                                                        bid (25)                                                                                                                                                                                                                                                                           
       Center unclear                                                                                                                                                                                                                                                                                                                                                                                                                                  bid (28)                                                                                                                                                                                                                                                                                                                                                                                    

  16   Jia et al. \[[@B126]\], China Monotherapy Single center      Randomized: method not mentioned; single blind: method not mentioned; parallel design; 60 days duration                         162 VaD patients; age: 54--71; duration: 0.8--3 yr                 DSM-4, CDR, imaging, HDS                                                                                                                                                        Luoshukang\                                                                                              Duxil 1 tablet\                                                                            MMSE, BBS, "protocol for new herbal drugs study on dementia"^∗\ b^                                                                                             N         N              N
                                                                                                                                                                                                                                                                                                                                                                                                                                                       1.5--2.5 g\                                                                                              bid (54)                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                       tid (108)                                                                                                                                                                                                                                                                                                                                                                                   

  17   Cheng et al. \[[@B127]\] Monotherapy Single center           Randomized: method not mentioned; single blind: method not mentioned; parallel design; 2 months duration                        36 VaD patients; age: 62--83; duration: 0.5--9 yr                  DSM-4-R, HIS, CT, MMSE, FAQ, HDS-R, ADL                                                                                                                                         Naozhitong 4\                                                                                            Nimodipine\                                                                                MMSE, FAQ, HDS-R, ADL, NO                                                                                                                                      N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       pcs tid (18)                                                                                             20 mg tid (18)                                                                                                                                                                                                                                                                     

  18   Liao et al. \[[@B73]\], China Monotherapy Single center      Randomized: computer-generated sequence; single blind: method not mentioned; parallel design; 2 months duration                 60 VaD patients; age: 71--74; duration: 3.2--5.6 hr                DSM-4, CT, MRI, HIS, MMSE, HDS, "TCM diagnostic criteria, differentiation and outcome measures on senile dementia"^∗c^                                                          Shoulingjiannao\                                                                                         Hydergine\                                                                                 MMSE, HDS, "protocol for the selection of anti-aging herbal medicine and the corresponding outcome measures"^∗\ d^                                             N         N              N
                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.9 g tid (32)                                                                                           1 mg tid (28)                                                                                                                                                                                                                                                                      

  19   Shen and Du \[[@B128]\], China Monotherapy Single center     Randomized: method not mentioned; single blind: method not mentioned; parallel design; 3 months duration                        70 VaD patients; age: 65--77; duration: 6 m --3 yr                 DSM-4, NINDS-AIREN, CT, MRI, "protocol for new herbal drugs study on dementia"^∗\ b^                                                                                            Bushenjianpiy-angxuehuoxue\                                                                              Hydergine\                                                                                 MMSE, ADL, ET, NO, HCY, E2, T                                                                                                                                  N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.9 g tid (40)                                                                                           2 mg tid (30)                                                                                                                                                                                                                                                                      

  20   Wang et al. \[[@B129]\], China Monotherapy Single center     Randomized: method not mentioned; double blind: details given; crossover design; 7 months duration (3 m + 1 m wash out + 3 m)   18 VaD patients; age: 54--83; duration: 1--7 yr                    DSM-4, CT, MRI, HDS, MMSE, ADL-R, "protocol for new herbal drugs study on dementia"^∗\ b^                                                                                       Shenlong\                                                                                                Placebo\                                                                                   HDS, MMSE-R, ADL-R, "protocol for new herbal drugs study on dementia" ^∗b^                                                                                     N         N              Y (2, mouth dryness, sore throat)
                                                                                                                                                                                                                                                                                                                                                                                                                                                       180 mL bid (18)                                                                                          180 mL bid (18)                                                                                                                                                                                                                                                                    

  21   Wang et al. \[[@B136]\], China Monotherapy Single center     Randomized: method not mentioned; single blind: method not mentioned; parallel design; 3 months duration                        100 VaD patients; age: 50--78; duration: 0.7--1.8 hr               DSM-4, HIS, ADL, MMSE, SDS, "TCM diagnostic criteria, differentiation and outcome measures on senile dementia"^∗\ c^, "protocol for new herbal drugs study on dementia"^∗\ b^   Huitian 0.8 g\                                                                                           Piracetam\                                                                                 MMSE, ADL, hemodynamic changes, "protocol for new herbal drugs study on dementia" ^∗b^                                                                         N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       tid (50)                                                                                                 08. g tid (50)                                                                                                                                                                                                                                                                     

  22   Wu et al. \[[@B83]\], China Monotherapy Center unclear       Randomized: method not mentioned; double blind: method not mentioned; parallel design; 30 days duration                         46 VaD patients; age: 62--77; duration: 0.8--4.7 yr                DSM-4, CCDVD, CDSVD-R, MMSE, HIS                                                                                                                                                Extract from *Herba Cistanches* 2 tablets tid (23)                                                       Hydergine 2\                                                                               MMSE, BBS, ADL, hemodynamic changes                                                                                                                            N         2              N
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                tablet tid (23)                                                                                                                                                                                                                                                                    

  23   Yu et al. \[[@B66]\], China Monotherapy Single center        Randomized: method not mentioned; single blind: method not mentioned; parallel design; 14 days duration                         123 VaD patients; age: 57--74; duration: 0.4--1.4 yr               DSM-4, "TCM diagnostic criteria, differentiation and outcome measures on senile dementia,"^∗\ c^ CT                                                                             Fucong 30 mL\                                                                                            Piracetam 0.8 g tid + vitamin E 0.1 g tid (51)                                             SOD, LPO, TG, TCH, HDL, EEG                                                                                                                                    N         N              Y (2, mouth dryness, sore throat)
                                                                                                                                                                                                                                                                                                                                                                                                                                                       od (72)                                                                                                                                                                                                                                                                                                                                                                                     

  24   Zhao \[[@B130]\], China Monotherapy Center unclear           Randomized: method not mentioned; double blinding not mentioned; Parallel design; 2 months duration                             90 VaD patients; age: 49--81; duration: 0.5--3.5 yr                DSM, CT, MRI, clinical presentation                                                                                                                                             Jiannaoqingxin\                                                                                          Duxil 1 tablet bid (40)                                                                    MMSE, MMSE-R, hemodynamic changes, HDS                                                                                                                         N         N              N
                                                                                                                                                                                                                                                                                                                                                                                                                                                       od (50)                                                                                                                                                                                                                                                                                                                                                                                     

  25   Feng et al. \[[@B86]\], China Monotherapy Single center      Randomized: method not mentioned; double blinding not mentioned; parallel design; 6 months duration                             50 VaD patients; age: 59--82; duration: 2--5 yr                    Portera-sanchey                                                                                                                                                                 Yizhi bid (30)                                                                                           Piracetam\                                                                                 MMSE, BBS, ADL                                                                                                                                                 N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1.6 g tid (20)                                                                                                                                                                                                                                                                     

  26   Liu \[[@B71]\], China Monotherapy Single center              Randomized: method not mentioned; no blinding is applied; parallel design; 2 months duration                                    142 VaD patients; age: 64--68; duration: 1.9--4.2 yr               DSM-R, CT, MRI, HIS                                                                                                                                                             Bushenyinao\                                                                                             Cerebroprot-ein Hydrolysate iv. 30 mL/day (44)                                             HDS, hemodynamic changes                                                                                                                                       N         46             Y
                                                                                                                                                                                                                                                                                                                                                                                                                                                       3 g tid (98)                                                                                                                                                                                                                                                                                                                                                                                

  27   Liu et al. \[[@B60]\], China Monotherapy Single center       Randomized: method not mentioned; double blinding not mentioned; parallel design; 2 months duration                             92 VaD patients; age: 45--80; duration: 1--12 yr                   DSM, MMSE, ADL, CDR, HIS, "protocol for new herbal drugs study on dementia"^∗\ b^                                                                                               Huatuozaizao\                                                                                            Duxil 1 tablet\                                                                            MMSE, ADL, TC, TG, HDL-C, ET, NO, SELF, "protocol for new herbal drugs study on dementia" ^∗b^                                                                 N         N              N
                                                                                                                                                                                                                                                                                                                                                                                                                                                       8 g tid (52)                                                                                             bid (40)                                                                                                                                                                                                                                                                           

  28   Liu and Chen \[[@B74]\], China Monotherapy Single center     Randomized: computer generated sequence; double blinding not mentioned; parallel design, 8 weeks duration                       86 hospitalized VaD patients; age: 60--79; duration: 4 m--6.5 yr   DSM-4, HDS, HIS                                                                                                                                                                 Buyanghuanwu\                                                                                            Hydergine\                                                                                 HDS, FAQ, hemodynamic changes, MQ, "protocol for new herbal drugs study on dementia"∗b                                                                         N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       12 g bid (43)                                                                                            1 mg bid (43)                                                                                                                                                                                                                                                                      

  29   Tang et al. \[[@B75]\], China Monotherapy Single center      Randomized: computer generated sequence; double blinding not mentioned; parallel design; 3 months duration                      80 VaD patients; age: 53--80; duration: 6 m--12 yr                 DSM-3-R, MMSE, CT, MRI, HIS, "TCM manual for neurological diseases"^∗\ e^                                                                                                       Bushenhuoxie bid (40)                                                                                    Duxil 1 tablet bid, Nimodipine 30 mg tid (40)                                              MMSE, ADL, WBHSV, WBLSV, PV, HCT, "TCM diagnostic criteria, differentiation and outcome measures on senile dementia"^∗\ c^                                     N         N              N

  30   Wang et al. \[[@B56]\], China Monotherapy Unclear center     Randomized: method not mentioned; double blind: details given; crossover design; 7 months duration (3 m + 1 m wash out + 3 m)   36 VaD patients; age: 52--83; duration: 1--7 yr.                   DSM-4, ADL-R                                                                                                                                                                    Shenlong\                                                                                                Placebo bid (36)                                                                           MMSE-R, BBS, HDS, ADL-R                                                                                                                                        N         N              Y (4, sore throat, mouth dryness)
                                                                                                                                                                                                                                                                                                                                                                                                                                                       180 mL bid (36)                                                                                                                                                                                                                                                                                                                                                                             

  31   Wang et al. \[[@B131]\], China Monotherapy Single center     Randomized: method not mentioned; double blinding not mentioned; parallel design; 3 months duration                             140 VaD patients; age: 50--78; duration: 0.9--1.8 yr               DSM-4, HIS, ADL, MMSE, SDS, "protocol for new herbal drugs study on dementia,"^∗\ b^ "TCM diagnostic criteria, differentiation and outcome measures on senile dementia" ^∗c^    Jiannaocongming\                                                                                         Piracetam\                                                                                 MMSE, ADL, hemodynamic changes                                                                                                                                 N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       100 mL tid (100)                                                                                         0.8 g tid (40)                                                                                                                                                                                                                                                                     

  32   Wang et al. \[[@B132]\], China Monotherapy Single center     Randomized: method not mentioned; double blinding not mentioned; parallel design; 6 months duration                             80 hospitalized VaD patients; age: 46--78; duration: 6--122 m      DSM-4, NINDS-AIREN, MMSE, HDS, FAQ, HIS, "protocol for new herbal drugs study on dementia"^∗b^                                                                                  Tongxinluo\                                                                                              Huperzine A\                                                                               MSME, HDS, FAQ, "TCM diagnostic criteria, differentiation and outcome measures on senile dementia"^∗\ c^                                                       N         N              Y (nausea, decrease in appetite, etc.)
                                                                                                                                                                                                                                                                                                                                                                                                                                                       3 pcs tid (40)                                                                                           0.1 mg bid (40)                                                                                                                                                                                                                                                                    

  33   Wang \[[@B133]\], China, Adjunct therapy Single center       Randomized: method not mentioned; double blinding not mentioned, parallel design; 45 days duration                              66 VaD patients; age: 51--76; duration: 0.5--6 yr                  DSM-4-R, MMSE, HDS, CT, MRI                                                                                                                                                     Buyanghuanwu od + Piracetam 1.2 g bid,\                                                                  Piracetam\                                                                                 HDS-R                                                                                                                                                          N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       Nimodipine 20 mg tid (33)                                                                                1.2 g bid, Nimodipine\                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                20 mg tid (33)                                                                                                                                                                                                                                                                     

  34   Zhou et al. \[[@B134]\], China Monotherapy Single center     Randomized: method not mentioned; double blinding not mentioned; parallel design; 3 months duration                             62 VaD patients; age: 59--76; duration: 0.5--6 yr                  CCMD-2-R, DSM-4, MMSE, HDS, HIS                                                                                                                                                 Yiqifuzhi\                                                                                               Piracetam\                                                                                 Hemodynamic changes, SOD, MDA, "protocol for new herbal drugs study on dementia"^∗\ b^                                                                         N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       46 g tid (30)                                                                                            0.8 g tid (32)                                                                                                                                                                                                                                                                     

  35   Gao \[[@B67]\], China Monotherapy Single center              Randomized: method not mentioned; double blinding not mentioned; parallel design; 3 months duration                             98 VaD patients; age: 54--75; duration: 0.2--1.8 yr                DSM-4, "TCM diagnostic criteria, differentiation and outcome measures on senile dementia"^∗\ c^, ADL, MMSE                                                                      Shumaiyinao\                                                                                             Piracetam\                                                                                 MMSE, hemodynamic changes, Vmin, Qmin, RI                                                                                                                      N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       1.2 g tid (58)                                                                                           1.2 g tid (40)                                                                                                                                                                                                                                                                     

  36   Hao et al. \[[@B135]\], China Monotherapy Single center      Randomized: method not mentioned; double blinding not mentioned; parallel design; 6 months duration                             100 VaD patients; age: 48--81; duration: 7--118 m                  ICD10, CT, MMSE, IADL, HIS                                                                                                                                                      Tongxinluo\                                                                                              Piracetam\                                                                                 MMSE, NPI, IADL, HIS                                                                                                                                           N         N              Y (16, GI discom-fort)
                                                                                                                                                                                                                                                                                                                                                                                                                                                       3 pcs tid (50)                                                                                           0.8 g tid (50)                                                                                                                                                                                                                                                                     

  37   Li et al. \[[@B61]\], China Monotherapy Single center        Randomized: method not mentioned; double blinding not mentioned; parallel design; 3 months duration                             60 VaD patients; age: 45--80; duration: 1--12 yr                   DSM-4, ADL, MMSE, HIS, "protocol for new herbal drugs study on dementia"^∗\ b^                                                                                                  Tongmaiyizhi\                                                                                            Duxil 1 tablet\                                                                            MMSE, ADL, "protocol for new herbal drugs study on dementia"^∗\ b^                                                                                             N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       8 g tid (30)                                                                                             bid (30)                                                                                                                                                                                                                                                                           

  38   Mou \[[@B68]\], China Monotherapy Unclear center             Randomized: method not mentioned; double blinding not mentioned; parallel design; 60 days duration                              60 VaD patients; age: 57--89; duration: 2.5--4 yr                  DSM-4, HDS                                                                                                                                                                      Self-derived\                                                                                            Nimodipine\                                                                                MMSE                                                                                                                                                           N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       CHM 16 g\                                                                                                30 mg tid (30)                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                       100 mL bid (30)                                                                                                                                                                                                                                                                                                                                                                             

  39   Shi and Wang \[[@B76]\], China\                              Randomized: computer generated sequence; double blind: method not mentioned; parallel design; 3 months duration                 78 VaD patients; age: 50--80+; duration: 5 m--1.5 yr               DSM-4, "TCM diagnostic criteria, differentiation and outcome measures on senile dementia,"^∗\ c^ "Diagnostic manual for geriatrics"^∗\ f^                                       Self-derived CHM 2 bid + nimodipine 40 mg tid, hydergine 2 mg tid (46)                                   nimodipine\                                                                                ADL, MMSE                                                                                                                                                      N         N              U
       Adjunct therapy\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         40 mg tid,\                                                                                                                                                                                                                                                                        
       Single center                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            hydergine\                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                2 mg tid (32)                                                                                                                                                                                                                                                                      

  40   Zhang and Lu \[[@B69]\], China Monotherapy Unclear center    Randomized: method not mentioned; double blinding not mentoned; parallel design; 3 months duration                              72 VaD patients; age: 57--71; duration: 0.3--5.6 yr                DSM-4, ICD10, HIS, HDL, TC                                                                                                                                                      Bushenjiannao\                                                                                           Piracetam\                                                                                 MMSE, HDS, hemodynamic changes, "protocol for new herbal drugs study on dementia"^∗b^                                                                          N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       300 mL bid (39)                                                                                          800 mg tid +\                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                hydergine\                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                2 tablet bid (34)                                                                                                                                                                                                                                                                  

  41   Chen et al. \[[@B84]\], China Monotherapy Single center      Randomized: method not mentioned; double blind: method not mentioned; parallel design; 3 months duration                        68 VaD patients; age: 60--86; duration: 1--7 yr                    DSM-4, HDS, MMSE, CT, MRI                                                                                                                                                       Shenlong\                                                                                                Piracetam\                                                                                 MMSE, BBS, HDS, "protocol for new herbal drugs study on dementia"^∗b^                                                                                          N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       600 mL/day (36)                                                                                          1.6 g tid (32)                                                                                                                                                                                                                                                                     

  42   Cui et al. \[[@B77]\], China Monotherapy Single center       Randomized: computer generated sequence; double blinding not mentioned; parallel design; 3 months duration                      67 VaD patients; age: 56--83; duration: 2 m--31 m                  DSM-4, NINDS-AIREN, HIS, CDR                                                                                                                                                    Shuangshencuzhi\                                                                                         Duxil 1 tablet\                                                                            MMSE, BBS, HCY, CT, MRI                                                                                                                                        N         5              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       8 g tid (51)                                                                                             bid (16)                                                                                                                                                                                                                                                                           

  43   He \[[@B57]\], China Monotherapy Single center               Randomized: method not mentioned; single blind: method not mentioned; parallel design; 8 weeks duration                         90 VaD patients; age: 48--80; duration: 2 m--6.5 yr                NINDS-AIREN, SDSVD, CDR, HIS, "criteria for the diagnosis, the differentiation of syndrome and the evaluation of efficacy of vascular dementia for research studies"^∗\ g^      Kangnao\                                                                                                 Hydergine\                                                                                 MMSE, hemodynamic changes, SELF                                                                                                                                N         N              N
                                                                                                                                                                                                                                                                                                                                                                                                                                                       6 g tid (60)                                                                                             2 mg tid (30)                                                                                                                                                                                                                                                                      

  44   Jin et al. \[[@B85]\], China Monotherapy Unclear center      Randomized: method not mentioned; double blind: details given; crossover design (12 w + 4 w wash out + 12 w);                   72 VaD patients; age: 55--83; duration: 1--7 yr                    DSM-4-R, MMSE, ADL, HDS, CT, MRI, "protocol for new herbal drugs study on dementia"^∗\ b^                                                                                       Jiannaoyizhi\                                                                                            Placebo tid (72)                                                                           MMSE-R, HDS, ADL-R, "protocol for new herbal drugs study on dementia"^∗b^, "protocol for new herbal drugs study on stroke"^∗\ b^                               N         N              Y (2, sore throat, mouth dryness)
                                                                                                                                                                                                                                                                                                                                                                                                                                                       2 g tid (72)                                                                                                                                                                                                                                                                                                                                                                                

  45   Yan \[[@B58]\], China Adjunct therapy Single center          Randomized: method not mentioned; double blinding not mentioned; parallel design; 1 month duration                              79 VaD patients; age: 51--78; duration: 0.5--9 yr.                 DSM-4-R, HDS-R, MMSE, CT, MRI                                                                                                                                                   Buyanghuanwu + Cerebroprotein Hydrolysate 10 mL 20 d, Aniracetam 0.12 g tid; Nimodipine 20 mg tid (36)   Cerebroprot-ein Hydrolysate 10 mL 20 d, Aniracetam 0.12 g tid; Nimodipine 20 mg tid (43)   HDS-R                                                                                                                                                          N         N              U

  46   Chang et al. \[[@B70]\], China Monotherapy Single center     Randomized: method not mentioned; double blinding not mentioned; parallel design; 12 weeks duration                             66 VaD patients; age: 60--78; duration: 1.3--3.6 yr                DSM-4, HIS, "TCM diagnostic criteria, differentiation and outcome measures on senile dementia,"^∗c^ MMSE, CT, MRI, HDS                                                          Qihong 300 mL\                                                                                           Piracetam 0.4 g bid (33)                                                                   HDS, MMSE                                                                                                                                                      N         N              U
                                                                                                                                                                                                                                                                                                                                                                                                                                                       bid (33)                                                                                                                                                                                                                                                                                                                                                                                    

  47   Li et al. \[[@B137]\], China Monotherapy Single center       Randomized: method not mentioned; double blinding not mentioned; parallel design; 2 months duration                             120 VaD patients; age: 59--75; duration: 0.6--6.2 yr               DSM-4, MMSE-R, CDR, NINDS-AIREN, SDSVD, HIS, CSDD, "protocol for new herbal drugs study on dementia"^∗\ b^                                                                      Shouwuyizhi\                                                                                             Piracetam 0.8 g tid (40)                                                                   MMSE, HDS, WMS, SDSVD, TCD, hemodynamic changes, SELF                                                                                                          N         N              N
                                                                                                                                                                                                                                                                                                                                                                                                                                                       2.4 g tid (80)                                                                                                                                                                                                                                                                                                                                                                              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Key: ^∗1^: N: intention-to-treat analysis is not used; Y: intention-to-treat analysis is applied.

^∗2^: N: no report of drop-out; Y: drop-out reported (with no. of dropouts in bracket).

^∗3^: N: report as no adverse events; Y: adverse events reported (with no. and details in bracket); U= adverse events unknown.

^∗a^: Quan et al. \[[@B117]\], ^∗b^: Guidance principle of clinical study on new drug of traditional Chinese medicine \[[@B118]\], ^∗c^: Fu \[[@B119]\], ^∗d^: Zhou \[[@B120]\], ^∗e^: Huang and Liu \[[@B121]\], ^∗f^: Wang et al. \[[@B122]\], ^∗f^: Tian et al. \[[@B88]\].

BEAM: brain electrical activity mapping
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